Management ChangeJun 18, 2026, 07:11 AM
Pfizer CFO Dave Denton to Depart; Cecile Guegan Named Interim CFO
AI Summary
Pfizer announced that Chief Financial Officer Dave Denton will step down from his role effective August 15, 2026, to pursue a professional opportunity outside the pharmaceutical industry in consumer goods. His departure is not due to any disagreements with the company's financial or operational policies. Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, will serve as Interim CFO starting August 16, 2026, while Pfizer conducts a comprehensive search for a permanent successor.
Key Highlights
- Dave Denton will step down as Pfizer's Chief Financial Officer on August 15, 2026.
- Denton is leaving for a professional opportunity outside the pharmaceutical industry.
- His departure is not related to any disagreements with Pfizer's financial policies.
- Cecile Guegan appointed Interim Chief Financial Officer, effective August 16, 2026.
- Ms. Guegan currently serves as SVP, Finance, Global Biopharmaceutical Business.
- Pfizer will conduct a comprehensive search for a permanent CFO successor.
- CEO Albert Bourla thanked Denton for leadership during Seagen, Biohaven, and Metsera transactions.
Price Impact
More from PFE